Evaluating a Novel Collaboration Between NOTCH1 and MLL1 for Improved Targeted Treatments in T-ALL


The Mark Foundation for Cancer Research-Leukemia & Lymphoma Society Fellow (2021-Present)

Therese Vu, PhD, University of Colorado Denver

Dr. Vu has been awarded a grant supporting her work to develop combination therapies to treat patients with T-cell acute lymphoblastic leukemia (T-ALL), a disease with a very poor prognosis. She is testing inhibitors targeting both the so-called mixed lineage leukemia 1 (MLL1) protein and the NOTCH1 protein, to weaken T-ALL cells and make them more susceptible to treatment.

Content courtesy of Leukemia & Lymphoma Society

BACK TO OUR PORTFOLIO